Abeona Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

FAIR VALUE MEASUREMENTS (Tables)

FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Mar. 31, 2023

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS

The following table provides a summary of financial assets measured at fair value on a recurring and non-recurring basis as of March 31, 2023 and December 31, 2022 (in thousands):

Description	Fair Value at March 31, 2023		Level 1		Level 2		Level 3

Recurring Assets
Cash equivalents
Money market fund	$	4,133	$	4,133	$	—	$	—
Short-term investments
U.S. treasury and federal agency securities		35,684		—		35,684		—
Total assets measured at fair value	$	39,817	$	4,133	$	35,684	$	—

Liabilities
Warrant liabilities	$	17,392		—		—	$	17,392
Total liabilities measured at fair value	$	17,392	$	—	$	—	$	17,392

Description	Fair Value at December 31, 2022		Level 1		Level 2		Level 3

Recurring Assets:
Cash equivalents
Money market fund	$	12,923	$	12,923	$	—	$	—
Short-term investments
U.S. treasury and federal agency securities		37,932		—		37,932		—
Total assets measured at fair value	$	50,855	$	12,923	$	37,932	$	—

Liabilities
Warrant liabilities	$	19,657		—		—	$	19,657
Total liabilities measured at fair value	$	19,657	$	—	$	—	$	19,657

SCHEDULE OF ESTIMATE FAIR VALUE OF WARRANTS

	As of March 31,
	2023		2022

Common share price	$	2.82	$	8.00
Expected term (years)		3.72 – 4.59		4.72
Risk-free interest rate (%)		3.56% – 3.65%		2.40%
Volatility (%)		103.82% – 110.51%		101.36%

SCHEDULE OF ACTIVITY OF WARRANT LIABILITIES

The following table provides a summary of the activity on the warrant liabilities (in thousands):


Warrant liabilities as of December 31, 2022	$	19,657
Gain recognized in earnings from change in fair value		(2,265	)
Loss recognized in earnings from change in fair value		-
Warrant liabilities as of March 31, 2023	$	17,392